Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
376.91+2.77 (+0.74%)
At close: 04:00PM EDT
376.91 0.00 (0.00%)
After hours: 04:15PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close374.14
Open373.71
Bid370.01 x 900
Ask565.21 x 900
Day's Range370.74 - 379.80
52 Week Range249.50 - 387.89
Volume330,485
Avg. Volume294,987
Market Cap19.645B
Beta (5Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-7.24
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est412.47
  • Benzinga

    Argenx's Drug Scores European Approval For Muscular Fatigue Disorder

    The European Commission has approved Argenx SE's (NASDAQ: ARGX) Vyvgart (efgartigimod alfa-fcab) as an add-on to standard therapy for generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody positive. gMG is characterized by weakness and rapid fatigue of any of the muscles under voluntary control. It's caused by a breakdown in the regular communication between nerves and muscles. Related: Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Sa

  • GlobeNewswire

    argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis

    VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p<0.0001) during the first treatment cycle in the Phase 3 ADAPT

  • Benzinga

    Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike

    HC Wainwright is bullish on Argenx SE's (NASDAQ: ARGX) Vyvgart (efgartigimod). "We think it's becoming obvious that Vyvgart is going to be a blockbuster sooner rather than later, as it establishes leadership in gMG and is poised to add new indications as well as a more patient-friendly SC formulation over the next 2-3 years," HC Wainwright notes. It raised the price target to $425 from $400. Vyvgart is approved for generalized myasthenia gravis (gMG), characterized by weakness and rapid fatigue

Advertisement
Advertisement